Gastric Cancer, Version 3.2016
Gastric Cancer, Version 3.2016
复制标题
DOI：
10.6004/jnccn.2016.0137
复制
发表时间：
2016-10-01
影响因子：
13.4
通讯作者：
Sundar, Hema
中科院分区：
文献类型：
--
作者：
Ajani, Jaffer A.;D'Amico, Thomas A.;Sundar, Hema
胃癌是世界上第五大最常见的癌症，也是第三大癌症死亡原因。在分期程序、成像技术和治疗方法方面已经取得了一些进展。NCCN肿瘤学临床实践指南（NCCN指南）为胃癌患者的管理提供了一种基于证据和共识的治疗方法。本文讨论了NCCN指南中概述的关于分期、评估HER2过表达、局部晚期或转移性疾病的全身治疗以及预防和管理晚期疾病症状的最佳支持治疗的建议。
Gastric cancer is the fifth most frequently diagnosed cancer and the third leading cause of death from cancer in the world. Several advances have been made in the staging procedures, imaging techniques, and treatment approaches. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Gastric Cancer provide an evidence- and consensus-based treatment approach for the management of patients with gastric cancer. This manuscript discusses the recommendations outlined in the NCCN Guidelines for staging, assessment of HER2 overexpression, systemic therapy for locally advanced or metastatic disease, and best supportive care for the prevention and management of symptoms due to advanced disease.